Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T47D Breast cancer cell line ChIP-seq data

ABSTRACT: We performed genome-wide PADI2 ChIP seq experiments in T47D cell lines and also RNP2 ChIP seq in T47D cells only expressing HA Tagged amanitin resistant wild type in comparison to R1810A mutant form of RNAP2.

ORGANISM(S): Homo sapiens

PROVIDER: GSE105793 | GEO | 2018/11/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

T47D RNA-seq and ChrRNA-seq data

Project description:We performed genome-wide RNA-seq and ChrRNA-seq experiments in T47D cell lines after PADI2 knock down . Both the mRNA and chromatin RNA seq peformed in sicontrol and siPADI2 as in biological replicates . Also we performed mRNA seq in T47D cells expressing HA Tagged amanitin resistant wild type in comparison to R1810A mutant form of RNAP2.

2018-11-21 | GSE105792 | GEO

T47D Breast cancer cell line ChIP-seq data II

Project description:We performed genome-wide CDK9 ChIP seq experiments in T47D cells only expressing HA Tagged amanitin resistant wild type in comparison to R1810A mutant form of RNAP2.

2018-11-21 | GSE113971 | GEO

Project description:We report the comprehensive genome-wide binding peaks for key factors inovled in oxygen sensing pathways, such as HIF1α, HIF1β and EglN2. In addition, we also report the genome-wide binding peaks for NRF1 in breast cancer cells We conducted HA-EglN2, HIF1α, HIF1β (ARNT) or NRF1 ChIP-Seq in the T47D cell line that overexpresses HA-EglN2 in the presence of hypoxia (1%) and DMOG treatment. T47D parental cells treated with the same condition followed by HA ChIP-seq served as the control to filter non-specific binding.

2014-07-31 | E-GEOD-59935 | biostudies-arrayexpress

Gene expression of T47D-MTVL human breast cancer cells upon H1.4 knock-down or overexpression

2014-05-16 | GSE55786 | GEO

T47D Breast cancer cell line ChIP-seq data

Project description:T47D Breast cancer cell line ChIP-seq data

| PRJNA415426 | ENA

Gene expression of T47D-MTVL human breast cancer cells upon H1.4 knock-down or overexpression

Project description:Gene expression of T47D-MTVL human breast cancer cells expressing Dox-inducible shRNAs against histone H1.4 (sh120) or multiple H1 variants (sh225), or overexpressing WT or K26A mutant HA-tagged H1.4. T47D-MTVL, breast cancer cell line carrying one stably integrated copy of luciferase reporter gene driven by the MMTV promoter, is stably infected with an inducible system for the expression of shRNAs.Cells stably express RedFP and KRAB repressor fused to Tet regulator.Upon Dox treatment, cells express RedFP and the cloned shRNA. Stable breast cancer-derived cell lines expressing an shRNA against one of each of the histone H1 isoforms in response to doxycycline (Dox) were grown for six days in the presence or absence of Dox, in duplicate, and RNA extracted for microarray hybridization. Cell lines used: inducible shRNA against H1.4 or multiple H1 variants, and random shRNA-expression vector. Stable breast cancer-derived cell lines expressing the histone H1.4 isoform, WT or K26A, HA-tagged, in duplicate, and RNA extracted for microarray hybridization. Cell lines used: overexpressing H1.4 WT or K26A mutant.

2014-05-16 | E-GEOD-55786 | biostudies-arrayexpress

T47D Breast cancer cell line ChIP-seq data II

Project description:T47D Breast cancer cell line ChIP-seq data II

| PRJNA454709 | ENA

T47D shNT versus T47D shRON

Project description:T47D shNT versus T47D shRON

| PRJNA682172 | ENA

H3.1 and H3.3 genome-wide profiling

Project description:ChIP-Seq of HA-tagged H3.1 and H3.3

| PRJEB27519 | ENA

RNA-seq transcriptome analyses in T47D cells treated with ActA and Palbociclib.

Project description:We performed SMAD2 ChIP-seq analysis in T47D cells with/without Palbociclib treatment. To validate whether the changes in SMAD2 binding to the genome indeed resulted in changes in target gene expression, we performed RNA-seq transcriptome analyses in T47D with/without ActA stimulation and Palbo treatment.

2018-10-23 | GSE117497 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data